All partnering requests
See more requests
- Background
- What we're looking for
- What we can offer you
- Q&A
Have questions about this request?
Get them answered by the team at the company.
Background
Many consumers struggle to fall asleep, stay asleep, or feel fully restored upon waking. While a variety of sleep aids exist, a common barrier to regular use is next day grogginess (e.g., residual sedation, impaired alertness, or “hangover” effects) that can interfere with work, driving, and daily functioning.
From a scientific perspective, next-day grogginess can arise from prolonged pharmacologic activity, non-selective receptor effects, disruption of normal sleep architecture, circadian misalignment, or slow clearance and metabolism. Consumers and clinicians increasingly seek solutions that improve sleep outcomes while preserving next-morning performance.
Advances in neuroscience, chronobiology, nutrition science, and drug delivery may enable new approaches that support sleep initiation and maintenance while minimizing residual effects.
What we're looking for
We are looking for evidence-based solutions for occasional sleeplessness that improve sleep onset and/or sleep maintenance while avoiding next day grogginess. We welcome proposals across three modalities described below. Hybrid solutions are encouraged when they improve efficacy and next morning functioning.
Solutions of interest include:
- Ingestible medicinal ingredients/formulations and dietary supplements designed to reduce next-day impairment (e.g., amino acids, botanicals, minerals, targeted blends)
- Wearables and non-invasive medical devices that provide sleep benefits such as Closed-Loop Auditory Stimulation (CLAS) or Closed-Loop Electrical Stimulation (tES/tACS) devices
- Technologies shaping delivery and pharmacokinetics (PK), including controlled release, timed dosing, microencapsulation (e.g., dual-phase release for onset + maintenance with morning washout)
Our must-have requirements are:
- Demonstrates measurable sleep benefit in preclinical, pilot, or clinical settings
- Designed to minimize next-day grogginess (alertness/performance preserved)
- Clear, reproducible mechanism of action and/or PK/PD rationale
- Preliminary safety profile appropriate for intended use
Our nice-to-have's are:
- Rapid onset (e.g., within 30–60 minutes) with minimal residual activity
- Demonstrates preserved next-morning alertness/performance in study measures
- OTC-friendly formats (gummy, capsule, beverage) with good sensory profile
- Compliant with applicable FDA/DSHEA regulations or clear path toward compliance
What's out of scope:
- Digital/behavioral programs, such as Cognitive Behavioral Therapy for Insomnia (CBT-I)–inspired, coaching, habit shaping
- Solutions that rely on strong residual sedation as the primary mechanism
- Approaches that increase next-day impairment risk (driving/work safety)
- Treatments intended for chronic insomnia without an occasional-use pathway
- Highly invasive/clinical administration that isn’t practical for routine use
Acceptable technology readiness levels (TRL):
Levels 4-9
What we can offer you
Eligible partnership models:
Sponsored researchCo-developmentSupply/purchaseLicensing
Benefits:
Sponsored Research
Funding is proposal dependent, with initial proof-of-concept projects typically ranging from $10,000 to $100,000 USD, depending on scope, technical maturity, and alignment with project objectives. Opportunities for additional funding may be considered based on performance and continued alignment.Expertise
Access to industry scientists experienced in sleep science, with regular technical discussions.Facilities and Services
For promising solutions, we may provide guidance or support toward regulatory strategy, safety assessment, and clinical validation pathways, helping partners translate innovative concepts into market-ready products.Tools and Technologies
Partners can send samples for on-site testing.Data
Where appropriate, partners may benefit from insights generated through internal testing, consumer understanding, and performance evaluation frameworks to help guide optimization and decision-making.Market Access
Opportunity to scale through global commercialization pathways, leveraging our capabilities in brand development, manufacturing, and distribution. High-performing technologies may be integrated into products deployed across multiple markets at scale.Q&A with the company
The Q&A is now closed.
Sort by:
Most upvoted
Q.
We are Hynt (hynt.net). Our personalised digital scent technology improves sleep and has been validated in controlled sleep studies and home deployments. Is this solution type within scope for the challenge?
1
Q.
I have a founder‑sealed, powder‑based circadian sleep system. What specific sleep or circadian pathway are you targeting, and what next‑day clarity outcome must be validated?”
JA
July 1, 2026
1
A.
We are looking for evidence-based solutions for occasional sleeplessness that improve sleep onset and/or sleep maintenance while avoiding next day grogginess. We are open to explore targets for any sleep or circadian pathway.
Subjective next morning data on improved sleep outcomes and absence of grogginess would be needed to validate the technology.
Is this response helpful?
0
0
Sign up to access the full partnering request.
View the details of this request and connect directly with corporate R&D teams at Fortune 500 companies.Already have an account? Sign in
Share partnering request
Complete
Refine recommendations
Is this request relevant to you?
Eligible partners
Academic researchersStartupsSuppliers
Seeking partners focused on
BiochemistryBiological ComplexityBiopharmaceuticsBotanyChronobiologyClinical PharmacologyCognitive NeuroscienceElectrophysiologyMedicinal ChemistryMetabolomics
10 more
Other recommended requests
NEW
Showcase solutions to industry
Don’t see a matching request for your technology, product, or service? List it and reach thousands of R&D decision-makers.
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.